These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 10073377)

  • 21. Concordance of patient and clinical ratings of symptom severity and change of psychotic illness.
    Rabinowitz J; Levine SZ; Medori R; Oosthuizen P; Koen L; Emsley R
    Schizophr Res; 2008 Mar; 100(1-3):359-60. PubMed ID: 18077138
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacoeconomics of schizophrenia in the 21st century.
    Hanson MA
    J Clin Psychiatry; 1999; 60 Suppl 1():26-7; discussion 28-30. PubMed ID: 10037168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [3 years of risperidone: from innovation to example].
    Nervenarzt; 1997 Apr; 68(4 Suppl Von Der In):1-4. PubMed ID: 9442496
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluating outcomes of treatments for persons with psychotic disorders.
    Lehman AF
    J Clin Psychiatry; 1996; 57 Suppl 11():61-7. PubMed ID: 8941172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: Description of study and effects on relapse rates.
    Hogarty GE; Kornblith SJ; Greenwald D; DiBarry AL; Cooley S; Ulrich RF; Carter M; Flesher S
    Am J Psychiatry; 1997 Nov; 154(11):1504-13. PubMed ID: 9356557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Examining the effectiveness of antipsychotic medication in first-episode psychosis.
    Taylor M; Cavanagh J; Hodgson R; Tiihonen J
    J Psychopharmacol; 2012 May; 26(5 Suppl):27-32. PubMed ID: 22337711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Veteran subjects willingness to participate in schizophrenia clinical trials.
    Hoblyn JC; Rosenheck RA; Leatherman S; Weil L; Lew R;
    Psychiatr Q; 2013 Jun; 84(2):209-18. PubMed ID: 23143523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risperidone versus Conventional Antipsychotics for Schizophrenia and Schizoaffective Disorder : Symptoms, Quality of Life and Resource Use under Customary Clinical Care.
    Mahmoud RA; Engelhart LM; Janagap CC; Oster G; Ollendorf D
    Clin Drug Investig; 2004; 24(5):275-86. PubMed ID: 17503889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Schizophrenia and quality of life--newly defined therapeutic targets].
    Psychiatr Prax; 1997 Nov; 24(6 Suppl Schizophre):1-4. PubMed ID: 9431365
    [No Abstract]   [Full Text] [Related]  

  • 30. Analysis of treatment effectiveness in longitudinal observational data.
    Faries D; Ascher-Svanum H; Belger M
    J Biopharm Stat; 2007; 17(5):809-26. PubMed ID: 17885867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Psychoeducation on Knowledge of and Attitude Toward Medications in Clients With Schizophrenia and Schizoaffective Disorders.
    Choe K; Sung BJ; Kang Y; Yoo SY
    Perspect Psychiatr Care; 2016 Apr; 52(2):113-9. PubMed ID: 25640073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study.
    Cortesi PA; Mencacci C; Luigi F; Pirfo E; Berto P; Sturkenboom MC; Lopes FL; Giustra MG; Mantovani LG; Scalone L
    BMC Psychiatry; 2013 Mar; 13():98. PubMed ID: 23522406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Schizophrenia and quality of life--therapeutic aims to be re-interpreted].
    Fortschr Neurol Psychiatr; 1998 Mar; 66(3 Suppl Fortschrit):1-4. PubMed ID: 9553759
    [No Abstract]   [Full Text] [Related]  

  • 34. Life satisfaction among individuals with schizophrenia in the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) study.
    Fervaha G; Agid O; Takeuchi H; Foussias G; Remington G
    Am J Psychiatry; 2013 Sep; 170(9):1061-2. PubMed ID: 24030617
    [No Abstract]   [Full Text] [Related]  

  • 35. First-episode psychosis in a managed care setting: clinical management and research.
    Jarskog LF; Mattioli MA; Perkins DO; Lieberman JA
    Am J Psychiatry; 2000 Jun; 157(6):878-84. PubMed ID: 10831465
    [No Abstract]   [Full Text] [Related]  

  • 36. Self-reported life satisfaction.
    Rohland BM; Langbehn DR
    Am J Psychiatry; 1997 Oct; 154(10):1478-9. PubMed ID: 9326847
    [No Abstract]   [Full Text] [Related]  

  • 37. The impact of managed care systems on relapse prevention and quality of life for patients with schizophrenia.
    Glazer WM
    Eur Neuropsychopharmacol; 1996; 6 Suppl 2():S35-9. PubMed ID: 8792119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intervention research in psychosis: issues related to the assessment of quality of life.
    Awad AG; Voruganti LN
    Schizophr Bull; 2000; 26(3):557-64. PubMed ID: 10993397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life rediscovered: implications for clinical outcome and health economics in schizophrenia.
    Awad AG
    J Psychiatry Neurosci; 1997 Jul; 22(4):229-30. PubMed ID: 9262043
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison of preferences for health outcomes in schizophrenia among stakeholder groups.
    Lee TT; Ziegler JK; Sommi R; Sugar C; Mahmoud R; Lenert LA
    J Psychiatr Res; 2000; 34(3):201-10. PubMed ID: 10867115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.